Point72 Asia Singapore Pte. Ltd. Acquires New Holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Point72 Asia Singapore Pte. Ltd. bought a new stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 25,303 shares of the company’s stock, valued at approximately $58,000.

A number of other large investors have also added to or reduced their stakes in the company. Norden Group LLC purchased a new position in shares of Ventyx Biosciences in the 1st quarter worth approximately $59,000. China Universal Asset Management Co. Ltd. grew its holdings in Ventyx Biosciences by 66.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,385 shares of the company’s stock worth $63,000 after purchasing an additional 4,553 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Ventyx Biosciences during the first quarter worth $72,000. SG Americas Securities LLC purchased a new stake in shares of Ventyx Biosciences during the 2nd quarter valued at $32,000. Finally, American Century Companies Inc. purchased a new stake in shares of Ventyx Biosciences during the 2nd quarter valued at $60,000. 97.88% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on VTYX shares. Canaccord Genuity Group reduced their target price on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Wells Fargo & Company cut their price objective on shares of Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a report on Monday, August 12th. HC Wainwright reiterated a “neutral” rating and issued a $6.00 target price on shares of Ventyx Biosciences in a research note on Monday, September 23rd. Finally, Oppenheimer dropped their target price on shares of Ventyx Biosciences from $12.00 to $10.00 and set an “outperform” rating on the stock in a research report on Thursday, June 6th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.29.

Ventyx Biosciences Trading Down 2.1 %

VTYX opened at $2.31 on Monday. Ventyx Biosciences, Inc. has a 12-month low of $1.79 and a 12-month high of $36.19. The firm has a 50 day moving average of $2.24 and a two-hundred day moving average of $3.56. The firm has a market capitalization of $162.85 million, a PE ratio of -0.71 and a beta of 0.37.

Ventyx Biosciences (NASDAQ:VTYX) last posted its earnings results on Thursday, August 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.12. As a group, analysts predict that Ventyx Biosciences, Inc. will post -2.14 EPS for the current fiscal year.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.